Short Bowel Syndrome Market

Short Bowel Syndrome Market “By Drug Type: (Glucagon-Like Peptide-2(Glp2), Growth Hormone, Glutamine, Anti-Diarrheal, Proton Pump Inhibitors And Others); By Diagnosis (Physical Exam, Faecal Tests, Imaging Procedures And Others); By Treatment (Nutritional Therapy, Medications, Surgery And Transplant); By Route Of Administration (Oral, Parenteral And Others); By End-Users (Hospitals, Homecare, Specialty Clinics And Others); By Distribution Channel (Hospital Pharmacy, Online Pharmacy And Retail Pharmacy)” - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

A prominent research firm, Cognizance Market Research added a cutting-edge industry report on "Short Bowel Syndrome Market". The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2023 to 2030.

Short Bowel Syndrome Market Analysis

According to cognizance market research the short bowel syndrome market is expected to register CAGR of 14.7% from 2023 to 2030.

What is Short Bowel Syndrome?

A portion of the small and/or large intestine may become physically absent or cease to operate, resulting in the complex disease known as short bowel syndrome. As a result, those who suffer from short bowel syndrome frequently have a decreased capacity for absorbing nutrients like lipids, carbohydrates (sugars), vitamins, minerals, trace elements, and fluids. (malabsorption). Short bowel syndrome symptoms can differ from person to person, as can their severity. Common, frequently serious, and potentially fatal dehydration are all effects of diarrhoea. Malnutrition, unintended weight loss, and other signs of short bowel syndrome may be brought on by a lack of vital vitamins and minerals. Although there is no cure, the condition is typically treatable successfully.

Depending on how well the small intestine is functioning, it can be mild, moderate, or severe in individuals. Additionally, individuals with short bowel syndrome are unable to absorb enough water, protein, fat, calories, minerals, and vitamins from their diet. Birth defects, gastrointestinal injuries, and intestinal illnesses are some of the causes of short bowel syndrome.

Short bowel syndrome, however, can occasionally result in serious, incapacitating, and even fatal consequences. Most frequently, the surgical removal (resection) of half or more of the small intestine leads to short bowel syndrome. These procedures are used to deal with inherited birth defects, small bowel injuries, and congenital intestinal diseases like Crohn's disease. The development and/or management of short bowel syndrome are both significantly influenced by the existence or absence of the large intestine (colon).

Short Bowel Syndrome Market

Short Bowel Syndrome Market Outlook

In the smart bowel syndrome report, the market outlook segment mainly includes important dynamics of the market which include drivers, restraints, opportunities and challenges tackled by the industry. Opportunities and challenges are extrinsic factors whereas, drivers and restraints are intrinsic factors of the market.

The rising incidence of this syndrome in countries such as the U.S., Canada, and the U.K. is increasing the need to develop innovative drug manufacturers to treat this condition. According to the data published by Crohn’s & Colitis Foundation, around 10,000 to 20,000 people have this condition in the U.S. Over the past few years, short intestine syndrome has become more common everywhere. The sector has grown more rapidly as a result of the rising number of patients receiving total parenteral nutrition.

Over the course of the forecast period, the development of the global market for short bowel syndrome medications may be restrained due to lack of qualified employees who are unable to treat patients with these medications. These types of syndromes are extremely expensive to treat, making them particularly costly for low-income groups. Lack of compensation guidelines and the restricted accessibility of authorized medications in nations like India, Africa, and others are further impeding market expansion.

Segment Analysis:

The short bowel syndrome market has been segmented into drug type, diagnosis, treatment, route of administration, end-users, distribution channel and geography.

Based on drug type the short bowel syndrome market is further segmented into glucagon-like peptide-2(GLP2), Growth hormone, glutamine, anti-diarrheal, proton pump inhibitors and others. The GLP 2 segment held a dominant share in the market. Growth hormone is anticipated to register a higher CAGR during the forecast period.

Based on diagnosis, the short bowel syndrome market is classified into physical exams, faecal tests, imaging procedures and other diagnosis. Based on treatment, the market for short bowel syndrome is further bifurcated into nutritional therapy, medications, surgery and transplant. Among the medication, Glucagon-Like Peptide-2(Glp2) accounted for about 80% share in the 2022, and expected to remain dominant over the estimated timeframe over the forecast period.

Based on route of administration, the short bowel syndrome market is further segmented into oral, parenteral and others. Based on end-users, the short bowel syndrome market is classified into hospitals, homecare, specialty clinics and others.

Based on distribution channel, the market for short bowel syndrome is bifurcated into hospital pharmacy, retail pharmacy and online pharmacy. The online and retail pharmacies segment is expected to generate the highest revenue among the distribution channel segment.

Geographical Analysis:

Based on geography the short bowel syndrome market has been segmented into five main regions namely, North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. The high prevalence of short bowel syndrome and increased research and development activity in North America have contributed to the region's positive growth in the global market for short bowel syndrome medications over the course of the anticipated era.

A large number of generic manufacturers, expanding healthcare infrastructure, and an increase in government efforts and specialized communities all contribute to Asia-Pacific's market dominance. During the years 2023-2030, growth in Latin America and the Middle East & Africa is anticipated to be substantial. The rise during the forecast period can be attributed to the increasing public awareness of rare diseases as well as the expanding need and demand for advanced products in these areas.

The report offers the revenue of the short bowel syndrome market for the period 2020-2030, considering 2020 & 2021 as a historical year, 2022 as the base year and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The short bowel syndrome market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the short bowel syndrome market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the short bowel syndrome market.

The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the short bowel syndrome market. Secondary research involved a detailed analysis of significant players’ product portfolio. Literature review, press releases, annual reports, white paper, and relevant documents have been also studied to understand the short bowel syndrome market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.

The report includes an executive summary, along with a growth pattern of different segmented included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the short bowel syndrome market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the short bowel syndrome market. The subsequent section of the short bowel syndrome report highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.



Short Bowel Syndrome Market Competitive Landscape

There are several well-known industry companies present in the moderately competitive short bowel syndrome market. Important market players are forming alliances with one another and buying market products, while other businesses are boosting their worldwide market share. Some of the major competitors in the short bowel syndrome market are as follows:

  • 9 Meters Biopharma, Inc.
  • Alvogen
  • Amneal Pharmaceuticals LLC.
  • Boehringer Ingelheim International GmbH
  • GSK Plc.
  • Hanmi Pharm.Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Novartis AG
  • Nutrinia Ltd.
  • Pharmascience, Inc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Johnsons & Johnsons Services Inc
  • Merck KGaA, Zealand Pharma A/S
  • OxThera
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • VectivBio AG


VectivBio Holding AG reported in June 2021 that the FDA had designated Apraglutide as an orphan medication. It is a long-acting, next-generation GLP-2 analog that is being created for the treatment of acute graft-versus-host disease and uncommon gastrointestinal disorders. (aGVHD).

Hanmi Pharm. Co. Ltd. reported in April 2021 that the U.S. FDA had given its short-bowel syndrome treatment, LAPS GLP-2 Analog, fast-track designation. (HM15912). A novel biopharmaceutical called LAPS GLP-2 Analog has been created for short bowel syndrome using the company's platform technology, Labscovery. The disorder has a survival rate of under 50%, affects children and teenagers' growth significantly and effects about 24.5 out of every 100,000 new-borns.

The report explores the competitive scenario of the shott bowel syndrome market. Major players operating in the short bowel syndrome market have been identified and profiled for unique commercial attributes. Company overview (company description, Type portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the short bowel syndrome market report.


Short Bowel Syndrome Market, by Drug Type

  • Glucagon-Like Peptide-2 (GLP2)
  • Growth Hormone
  • Glutamine
  • Anti-Diarrheal
  • Proton Pump Inhibitors
  • Others

Short Bowel Syndrome Market, by Diagnosis

  • Physical Exam
  • Faecal Tests
  • Imaging Procedures
  • Others

Short Bowel Syndrome Market, by Treatment

  • Nutritional Therapy
  • Medications
  • Surgery
  • Transplant

Short Bowel Syndrome Market, by Route of Administration

  • Oral
  • Parenteral
  • Others

Short Bowel Syndrome Market, by End-User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Short Bowel Syndrome Market, by Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Short bowel syndrome Market, by Region

  • North America
    • S.
    • Canada
  • Europe
    • Germany
    • K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Request Type(Required)

- Select Licence Type -

Licence Type(Required)